Clik here to view.
RTI Surgical names new CEO, parts ways with CSO Hartill | Personnel Moves |...
RTI Surgical (NSDQ:RTIX) named Camille Farhat as its chief executive officer, effective March 15, 2017. Previously, Farhat served as president & CEO of American Medical Systems, Inc., where he...
View ArticleClik here to view.
Lombard Medical CEO Hubbert, CFO Kullback step down | Personnel Moves, April...
Lombard Medical Technologies (NSDQ:EVAR) said this month that its CEO Simon Hubbert and CFO William Kullback are stepping down from their positions, with Kurt Lemvigh stepping into the CEO role....
View ArticleClik here to view.
Senseonics, TypeZero ink development deal for artificial pancreas
Senseonics (NYSE:SENS) said yesterday that it inked a non-exclusive R&D license agreement with TypeZero Technologies to develop artificial pancreas and decision support systems for its Eversense...
View ArticleClik here to view.
Senseonics inks artificial pancreas deal with Roche, TypeZero Technologies
Senseonics (NYSE:SENS) said today that it inked a collaboration with TypeZero Technologies and Roche (OTC:RHHBY) Diabetes Care to develop an automated insulin delivery system. The deal is part of an...
View ArticleClik here to view.
Senseonics expects FDA panel to consider Eversense CGM clearance
Senseonics (NYSE:SENS) said it expects the FDA will convene a special panel as it considers the company’s implantable Eversense continuous glucose monitors. The clarity came during the company’s 2nd...
View ArticleClik here to view.
Senseonics prices $25m offering
Senseonics (NYSE:SENS) today priced an upcoming offering, looking to raise approximately $25 million to support its Eversense long-term implantable continuous glucose monitoring system. The...
View ArticleClik here to view.
Senseonics wins CE Mark for Eversense XL glucose monitor
Senseonics (NYSE:SENS) said yesterday that it won CE Mark approval in the European Union for its Eversense XL continuous glucose monitor. The Eversense XL includes a glucose sensor designed to be...
View ArticleClik here to view.
Senseonics tops sales estimates with Q3 results
Shares in Senseonics (NYSE:SENS) fell today even though the medical technology company beat expectations on Wall Street with its third quarter results. The Germantown, Md.-based company posted a loss...
View ArticleClik here to view.
Amniox Medical taps ex-Smith & Nephew honcho Dugan for CEO | Personnel Moves
Amniox Medical said it named former Smith & Nephew (FTSE:SN, NYSE:SNN) executive Thomas Dugan as its new CEO. Amniox, a subsidiary of TissueTech, makes amniotic membrane- and umbilical cord-based...
View ArticleClik here to view.
Senseonics prices $50m notes offering, touts Q4 and full-year prelims
Senseonics (NYSE:SENS) announced today an underwritten offering of $50 million in 5.25% convertible senior notes due 2023, alongside a 30-day option for underwriters to buy up to an additional $7.5...
View ArticleClik here to view.
Senseonics’ implantable glucose monitor succeeds in 90-day trial
A 90-day trial involving patients with Type I and Type II diabetes showed that Senseonics‘ (NYSE:SENS) implantable continuous glucose monitor was safe and accurate compared to reference glucose values,...
View ArticleClik here to view.
FDA panel to review Senseonics’ implantable CGM this month
A panel for the FDA is slated to review Senseonics‘ (NYSE:SENS) premarket approval application for its Eversense implantable continuous glucose monitoring system on March 29. The company’s device sends...
View ArticleClik here to view.
Senseonics tops Q4 EPS estimates, misses sales expectations
Shares in Senseonics (NYSE:SENS) closed down -3% yesterday after the medical device maker met earnings expectations on Wall Street with its fourth quarter and full-year financial results, but narrowly...
View ArticleClik here to view.
FDA committee backs Senseonics’ implantable continuous glucose monitor
An FDA advisory panel voted unanimously to recommend approval for Senseonics‘ (NYSE:SENS) implantable continuous glucose monitor, Eversense, the company touted this week. The panel of medical experts...
View ArticleClik here to view.
Senseonics Q1 misses on EPS
Shares in Senseonics (NYSE:SENS) have fallen slightly today after the continuous glucose monitoring-focused medtech company posted first quarter earnings that missed on earnings per share expectations...
View ArticleClik here to view.
Beta Bionics taps Senseonics’ implantable glucose monitor for artificial...
Senseonics‘ (NYSE:SENS) said today that it inked a deal to integrate glucose data from its Eversense continuous glucose monitoring system into Beta Bionics‘ investigational iLet bionic pancreas....
View ArticleClik here to view.
FDA approves Senseonics’ implantable continuous glucose monitor
The FDA this week approved Senseonics‘ (NYSE:SENS) Eversense continuous glucose monitor for use in people ages 18 and older with diabetes. The device is the first CGM system to feature an implantable...
View ArticleClik here to view.
Senseonics prices $130m public offering
On the heels of an FDA approval for its implantable continuous glucose monitoring tech, Senseonics‘ (NYSE:SENS) today priced a $130 million underwritten public offering of common stock. The offering,...
View ArticleClik here to view.
Senseonics closes $150m public offering
Senseonics (NYSE:SENS) said today that it closed an underwritten public offering of its common stock, reeling in $149.5 million in total proceeds. The Germantown, Md.-based company plans to use its...
View ArticleClik here to view.
Senseonics inks diabetes management deal with Glooko
Senseonics (NYSE:SENS) said today that it inked a global deal to integrate its Eversense continuous glucose monitoring system with Glooko‘s diabetes data management tech. Users will be able to sync...
View Article